Last reviewed · How we verify
Topical latanoprost 0.005%
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Topical latanoprost 0.005% |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost acts as a selective agonist at the prostaglandin F (FP) receptor, primarily located on the ciliary muscle bundle and trabecular meshwork of the eye. By activating these receptors, it enhances drainage of aqueous humor through the unconventional uveoscleral pathway, reducing intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2, PHASE3)
- Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension (PHASE1)
- The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)
- A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma (PHASE4)
- The Laser in Pseudoexfoliation (LIP) Study (PHASE4)
- Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo. (PHASE2, PHASE3)
- Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- African Glaucoma Laser Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: